This could indicate that parts of the tumor with the most actively proliferating cells were least impacted by KRAS-driven inflammation, or that tumor cells modulate their KRAS-driven associated inflammation during proliferation (Fig. 2d,e and Methods). This evidence concerns the gene KRAS and neoplasm.